EUROPEAN COMMISSION
HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Health systems and products
Medicinal products – quality, safety and efficacy
Head of Unit

Brussels,
SANCO/MSW/ia/ddg1.d.6(2014)4615574
Sent by e-mail only

Dear Mr Báldi,

Subject: Diclofenac

Thank you for your letter dated 17 November 2014 sent to the attention of Commissioner Andriukaitis in which you have expressed concerns regarding the authorisation of veterinary medicines containing diclofenac and requested the Commission to revoke their licensing in the EU. Commissioner Andriukaitis has asked me to reply to you on his behalf.

As you may be aware, the Commission took the initiative to submit a request for scientific advice to the European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) as to whether or not veterinary medicines containing diclofenac present a risk for vultures and other necrophagous birds in Europe.

The EMA issued its advice on 12 December 2014. The Commission will now examine this advice carefully in order to take an informed decision on the appropriate course of action.

Yours sincerely,

Stefano Soro

András Báldi
President
Society for Conservation Biology
Europe Section
e-mail: europe@conbio.org

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111
Office: DM24 02/042 - Tel. direct line +32 229-97862 - Fax +32 229-81287
martha.spagnuolo-weaver@ec.europa.eu